Premium
Endothelial Progenitor Cell‐Derived Extracellular Vesicles: A Novel Candidate for Regenerative Medicine and Disease Treatment
Author(s) -
Xing Zheng,
Zhao Chen,
Liu Haifeng,
Fan Yubo
Publication year - 2020
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202000255
Subject(s) - progenitor cell , regenerative medicine , paracrine signalling , microvesicles , angiogenesis , endothelial progenitor cell , extracellular vesicles , microbiology and biotechnology , mediator , biology , extracellular vesicle , regeneration (biology) , cell type , secretion , cell , stem cell , cancer research , microrna , biochemistry , receptor , gene
Extracellular vesicles (EVs) are a heterogeneous group of membranous structures, which can be secreted by most cell types. As a product of paracrine secretion, EVs are considered to be a regulatory mediator for intercellular communication. There are many bioactive cargos in EVs, such as proteins, lipids, and nucleic acids. As the precursor cell of vascular endothelial cells (ECs), endothelial progenitor cells (EPCs) are first discovered in peripheral blood. With the development of studies about the functions of EPCs, an increasing number of researchers focus on EPC‐derived EVs (EPC‐EVs). EPC‐EVs exert key functions for promoting angiogenesis in regenerative medicine and show significant therapeutic effects on a variety of diseases such as circulatory diseases, kidney diseases, diabetes, bone diseases, and tissue/organ damages. This article reviews the current knowledge on the role of EPC‐EVs in regenerative medicine and disease treatment, discussing the main challenges and future directions in this field.